Further analysis showed that the effects of Vericiguat combined with “ARNI, BB, SGLT2i” on cardiac function in patients with DCM HFpEF were compared before and after 1 month of treatment: LVEF (53.4% ± 3.6% vs. 56.4% ± 4.7%, P < 0.05); LVEDD (55.6 ± 4.6 vs. 54.0 ± 3.5 mm, P = 0.056); NT-proBNP (1,484.3 ± 231 vs. 556.1 ± 432.3 ng/L, P < 0.01), as shown in Figure 4. This evidence concerns the gene NPPB and familial dilated cardiomyopathy.